The global sinus dilation devices market size is estimated to reach USD 5.69 billion by 2030, registering a CAGR of 9.6%, according to a new report by Grand View Research, Inc. Changes in lifestyle, increasing cases of obesity, and a resultant rise in the incidence of sinus-related conditions are the major factors contributing to the market growth. The introduction of technologically advanced devices is also one of the key factors boosting market growth. Major market players are focusing on R&D activities to introduce minimally invasive procedures creating a positive impact on the adoption of MIS procedures.
Some of the inventions in the market related to endoscopic approaches include a nasal endoscope, rhinoscopes, and balloon sinus dilation devices. An increase in medical reimbursements across major markets is likely to fuel the market growth. Rising adoption of health insurance and growing per capita expenditure coupled in developed as well as developing countries is predicted to augment the market growth.
In November 2017, Entellus Medical, Inc. announced that Anthem, Inc., an American health insurance company, provided insurance coverage for Balloon Sinus Dilation (BSD) used in the treatment of recurrent acute sinusitis and chronic sinusitis. Anthem, Inc. is a member of the Blue Cross Blue Shield Association, the second-largest health benefits plan provider that covers around 40 million people in the U.S. Other major health insurance companies providing coverage for standalone BSD are Medicare, Aetna, Cigna, TRICARE, Humana, Health Net, Kaiser, and United Healthcare.
Gather more insights about the market drivers, restrains and growth of the Sinus Dilation Devices Market
Detailed Segmentation:
Application Insights
The adult patient segment accounted for the highest revenue share of more than 65% in 2022, owing to the high prevalence of sinusitis in adults. According to the Centers for Disease Control and Prevention (CDC), over 28 million adults in the U.S. have been diagnosed with sinusitis. This condition affects about 11.6% of all adults in the country. Sinusitis is a common health issue where the sinuses, which are air-filled spaces in the face, become inflamed and can cause symptoms such as nasal congestion, facial pain, and headaches. It's essential to manage sinusitis properly to alleviate discomfort and improve overall health.
Regional Insights
North America dominates the sinus dilation devices market in terms of revenue, accounting for a share of over 40% in 2022. The dominance can be attributed to highly regulated and developed healthcare infrastructure. Moreover, the availability of advanced products due to the presence of major market players is boosting market growth.
According to The Commonwealth Fund, the healthcare system in the U.S. is a combination of public and private organizations. The federal government funds programs such as Medicare for older adults and some people with disabilities, as well as programs for veterans and low-income individuals such as Medicaid and the Children's Health Insurance Program. States also manage some local coverage and safety net programs. Many people have private health insurance provided by their employers, the most common type of coverage. The number of people without insurance has decreased over the years due to the Affordable Care Act. Both public and private insurers decide what services they will cover and how much individuals have to pay, following certain rules and regulations set by the federal and state governments. In simple terms, the US healthcare system involves a mix of government-funded and private insurance options that provide coverage to different groups of people.
Product Insights
The Balloon Sinus Dilation (BSD) devices segment captured the largest revenue share of more than 45% in 2022. BSDs are safe, small, flexible, and effective in improving symptoms of sinusitis. As the sinus dilation procedure does not involve tissue ablation, it results in quick turnaround time and patient comfort. However, BSD procedures are temporary, and patients may have to undergo repeat procedures. Balloon sinuplasty is used to treat chronic rhinosinusitis (CRS), a long-term inflammation of the sinuses.
Type Insights
The sinuscopes segment captured the largest revenue share of around 60% in 2022 and is expected to grow at a CAGR of 9.5% over the forecast period. Growing preference for minimally invasive procedures and advances in sinuscope technology are expected to drive segment growth. For instance, in 2017, Stryker launched the Stryker VR Sinus Surgery Simulator, which helps surgeons train for sinus surgeries. The simulator uses a realistic 3D model of the sinuses to create a virtual environment for surgeons to practice their skills. The simulator also provides feedback on the surgeon's performance, which can help them to improve their skills.
Procedure Insights
The standalone procedure segment captured the highest revenue share of over 65% in 2022. Balloon sinus ostial dilation is performed as a standalone procedure. Standalone balloon dilation is as effective as functional endoscopic sinus surgery for treating chronic rhinosinusitis. In addition, the rising preference for minimally invasive surgical procedures due to increased adoption of health insurance is anticipated to fuel segment growth.
According to census.gov, between 2020 and 2021, there was a slight decline in the number of uninsured people in the U.S. In 2020, 8.6% of the population, equivalent to 28.3 million individuals, lacked health insurance throughout the year. This number decreased to 8.3% in 2021, with approximately 27.2 million uninsured people. Private health insurance coverage remained more common than public coverage in 2021. About 66.0% of individuals had private health insurance, while 35.7% had public coverage. Employer-based insurance was the most prevalent type among those with private health insurance, covering 54.3% of the population. On the other hand, Medicaid was the most common form of public health insurance, providing coverage to 18.9% of the population.
End-use Insights
The hospitals segment accounted for the largest revenue share of around 50% in 2022 and is expected to witness considerable growth during the forecast period owing to the high volume of surgical procedures performed in hospitals. The increasing prevalence of chronic sinusitis coupled with favorable reimbursement criteria is anticipated to boost the segment growth. The availability of technologically advanced infrastructure and medical equipment along with the ability to perform complex sinus surgeries are projected to boost segment growth.
Browse through Grand View Research's Medical Devices Industry Research Reports.
• The global breast shells market size was valued at USD 71.0 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2030.
• The global biosimilar contract manufacturing market was valued at USD 8.59 billion in 2023 and is expected to grow at a CAGR of 15.9% during the forecast period.
Key Companies & Market Share Insights
Key players in the market are focusing on adopting growth strategies, such as mergers and acquisitions, developing existing devices, promotional events, and technological advancements. For instance, Intersect ENT, Inc., one of the leading medical technology companies for ear, nose, and throat care, introduced a new product in the U.S. called the Straight Delivery System (SDS) along with the PROPEL Mini Sinus Implant (a medical device). The U.S. Food and Drug Administration has approved this combined packaging, making it available for use. The Straight Delivery System was previously approved in July 2020. In simple terms, Intersect ENT has launched a new product in the U.S. that includes a medical device called the SDS and the PROPEL Mini Sinus Implant, which the FDA has approved for use.
Key Sinus Dilation Devices Companies:
• Medtronic
• Smith+Nephew
• Stryker
• Intersect ENT, Inc
• Olympus Corporation
• SinuSys Corporation
• Johnson & Johnson Services, Inc.
• TE Connectivity
• InnAccel Technologies Pvt Ltd
Sinus Dilation Devices Market Segmentation
Grand View Research has segmented the global sinus dilation device market on the basis of product, type, procedure, application, end-use, and region:
Sinus Dilation Devices Product Outlook (Revenue in USD Million, 2018 - 2030)
• Balloon Sinus Dilation Devices
• Endoscope
• Sinus Stents/Implants
• Functional Endoscopic Sinus Surgery (FESS) Instruments Set
• Others
Sinus Dilation Devices Type Outlook (Revenue in USD Million, 2018 - 2030)
• Sinusoscope
• Rhinoscope
Sinus Dilation Devices Procedure Outlook (Revenue in USD Million, 2018 - 2030)
• Standalone
• Hybrid
Sinus Dilation Devices Application Outlook (Revenue in USD Million, 2018 - 2030)
• Adult
• Pediatric
Sinus Dilation Devices End-use Outlook (Revenue in USD Million, 2018 - 2030)
• Hospitals
• Ambulatory Surgical Centers
• ENT Clinics/In Office
Sinus Dilation Devices Regional Outlook (Revenue in USD Million, 2018 - 2030)
• North America
or US
or Canada
• Europe
o UK
or Germany
or France
or Italy
or Spain
o Denmark
or Sweden
or Norway
• Asia Pacific
or Japan
o China
o India
or Australia
or Thailand
o South Korea
• Latin America
or Brazil
or Mexico
or Argentina
• Middle East and Africa
o South Africa
o Saudi Arabia
o UAE
or Kuwait
Order a free sample PDF of the Sinus Dilation Devices Market Intelligence Study, published by Grand View Research.
